In the past week, PACB stock has gone down by -51.10%, with a monthly decline of -59.42% and a quarterly plunge of -76.48%. The volatility ratio for the week is 23.33%, and the volatility levels for the last 30 days are 11.03% for Pacific Biosciences of California Inc The simple moving average for the past 20 days is -50.99% for PACB’s stock, with a -80.87% simple moving average for the past 200 days.
Is It Worth Investing in Pacific Biosciences of California Inc (NASDAQ: PACB) Right Now?
Additionally, the 36-month beta value for PACB is 2.01. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for PACB is 255.73M and currently, short sellers hold a 19.18% ratio of that float. The average trading volume of PACB on April 22, 2024 was 9.61M shares.
PACB) stock’s latest price update
The stock price of Pacific Biosciences of California Inc (NASDAQ: PACB) has surged by 6.16 when compared to previous closing price of 1.46, but the company has seen a -51.10% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-17 that PacBio’s (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.
Analysts’ Opinion of PACB
Many brokerage firms have already submitted their reports for PACB stocks, with Goldman repeating the rating for PACB by listing it as a “Neutral.” The predicted price for PACB in the upcoming period, according to Goldman is $2.50 based on the research report published on April 18, 2024 of the current year 2024.
Stephens, on the other hand, stated in their research note that they expect to see PACB reach a price target of $11. The rating they have provided for PACB stocks is “Overweight” according to the report published on December 14th, 2023.
PACB Trading at -64.14% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.35% of loss for the given period.
Volatility was left at 11.03%, however, over the last 30 days, the volatility rate increased by 23.33%, as shares sank -59.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -75.47% lower at present.
During the last 5 trading sessions, PACB fell by -51.10%, which changed the moving average for the period of 200-days by -87.94% in comparison to the 20-day moving average, which settled at $3.0482. In addition, Pacific Biosciences of California Inc saw -84.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PACB starting from Meline David W, who purchase 40,000 shares at the price of $4.40 back on Mar 06 ’24. After this action, Meline David W now owns 40,000 shares of Pacific Biosciences of California Inc, valued at $176,160 using the latest closing price.
HENRY CHRISTIAN O, the of Pacific Biosciences of California Inc, sale 14,177 shares at $4.87 during a trade that took place back on Mar 04 ’24, which means that HENRY CHRISTIAN O is holding 2,596,670 shares at $69,056 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -1.66 for the present operating margin
- 0.27 for the gross margin
The net margin for Pacific Biosciences of California Inc stands at -1.5. The total capital return value is set at -0.2. Equity return is now at value -48.53, with -17.46 for asset returns.
Based on Pacific Biosciences of California Inc (PACB), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at -0.29. The debt to equity ratio resting at 1.29. The interest coverage ratio of the stock is -23.24.
Currently, EBITDA for the company is -277.67 million with net debt to EBITDA at -2.64. When we switch over and look at the enterprise to sales, we see a ratio of 5.83. The receivables turnover for the company is 5.48for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.81.
Conclusion
In conclusion, Pacific Biosciences of California Inc (PACB) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
